Big diabetes – big pharma’s big bucks!

Top diabetes drug pipelines of 2012:

FierceBiotech has drilled into most of the largest pipelines of Type 2 diabetes drugs in the world, finding that there are more than 100 new therapies for patients with the disease in mid- to late-stage clinical trials, according to data from Relay Technology Management. And drugmakers are aggressively pursuing new treatments for what Standard & Poor's analysts reported last week is an annual market poised to jump from $35 billion now to $58 billion by 2018.

1 AstraZeneca/Bristol-Myers Squibb--Dapagliflozin

2 Johnson & Johnson--Canagliflozin

3 Eli Lilly/Boehringer Ingelheim--LY2605541

4 Merck & Co.--MK-3102

5 Novo Nordisk--Tresiba

6 Sanofi--Lyxumia

7 Takeda--Nesina